Sogroya® hits the Canadian market as a once-weekly growth hormone option Novo Nordisk has announced that Sogroya® (somapacitan injection) is now commercially available in Canada, marking a new milestone for growth hormone deficiency (GHD) treatment. Sogroya® is indicated for the long-term management of pediatric patients with growth failure due to inadequate endogenous growth hormone and…